Sebastian Michels1, Andreas Hans Scheel2, Matthias Scheffler1, Anne Maria Schultheis2, Oliver Gautschi3, Franziska Aebersold4, Joachim Diebold4, Georg Pall5, Sacha Rothschild6, Lukas Bubendorf7, Wolfgang Hartmann8, Lukas Heukamp2, Hans-Ulrich Schildhaus9, Jana Fassunke2, Michaela Angelika Ihle2, Helen Künstlinger2, Carina Heydt2, Rieke Fischer1, Lucia Nogovà1, Christian Mattonet1, Rebecca Hein10, Anne Adams10, Ulrich Gerigk11, Wolfgang Schulte12, Heike Lüders13, Christian Grohé13, Ullrich Graeven14, Clemens Müller-Naendrup15, Andreas Draube16, Karl-Otto Kambartel17, Stefan Krüger18, Susanne Schulze-Olden18, Monika Serke19, Walburga Engel-Riedel20, Britta Kaminsky21, Winfried Randerath21, Sabine Merkelbach-Bruse2, Reinhard Büttner2, Jürgen Wolf22. 1. Center for Integrated Oncology Köln Bonn, Cologne, Germany; Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany; Network Genomic Medicine, Cologne, Germany. 2. Network Genomic Medicine, Cologne, Germany; Institute of Pathology, University Hospital of Cologne, Cologne, Germany. 3. Department for Medical Oncology, Lucerne Cantonal Hospital, Lucerne, Switzerland. 4. Institute of Pathology, Lucerne Cantonal Hospital, Lucerne, Switzerland. 5. Department for Internal Medicine, Haematology and Oncology, University Hospital Innsbruck, Innsbruck, Austria. 6. Department for Oncology, University Hospital Basel, Basel, Switzerland. 7. Department for Cytopathology, University Hospital Basel, Basel, Switzerland. 8. Gerhard-Domagk-Institute of Pathology, University Hospital of Münster, Münster, Germany. 9. Institute of Pathology, University Hospital of Göttigen, Göttingen, Germany. 10. Institute of Medical Statistics, Informatics and Epidemiology, University Hospital of Cologne, Cologne, Germany. 11. Thoracic Centre, Malteser Hospital Bonn/Rhein-Sieg, Bonn, Germany. 12. Departent for Pulmonology Cardiology and Allergology, Johanniter Hospital, Bonn, Germany. 13. Evangelic Lung Clinic Berlin, Department of Pneumology, Berlin, Germany. 14. Department for Hematology, Oncology and Gastroenterology, Maria Hilf Hospital Mönchengladbach, Mönchengladbach, Germany. 15. Private Practice for Oncology, Medical Centre II (Martinus Höfe), Olpe, Germany. 16. Department for Internal Medicine, St. Vinzenz Hospital Cologne, Cologne, Germany. 17. Department for Pulmonology and Allergology, Bethanien Hospital Moers, Moers, Germany. 18. Department for Pulmonology/Allergology/Sleep Medicine and Respiratory Care, Florence-Nightingale-Hospital, Düsseldorf, Germany. 19. Department for Pulmonology and Thoracic Oncology, Lung Clinic Hemer, Hemer, Germany. 20. Lung Clinic Merheim, Hospitals of Cologne, Cologne, Germany. 21. Clinic for Pulmonology and Allergology, Bethanien Hospital, Solingen, Germany. 22. Center for Integrated Oncology Köln Bonn, Cologne, Germany; Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany; Network Genomic Medicine, Cologne, Germany. Electronic address: juergen.wolf@uk-koeln.de.
Abstract
INTRODUCTION: Rearrangements of RET are rare oncogenic events in patients with non-small cell lung cancer (NSCLC). While the characterization of Asian patients suggests a predominance of nonsmokers of young age in this genetically defined lung cancer subgroup, little is known about the characteristics of non-Asian patients. We present the results of an analysis of a European cohort of patients with RET rearranged NSCLC. METHODS: Nine hundred ninety-seven patients with KRAS/EGFR/ALK wildtype lung adenocarcinomas were analyzed using fluorescence in situ hybridization for RET fusions. Tumor specimens were molecularly profiled and clinicopathological characteristics of the patients were collected. RESULTS: Rearrangements of RET were identified in 22 patients, with a prevalence of 2.2% in the KRAS/EGFR/ALK wildtype subgroup. Co-occurring genetic aberrations were detected in 10 patients, and the majority had mutations in TP53. The median age at diagnosis was 62 years (range, 39-80 years; mean ± SD, 61 ± 11.7 years) with a higher proportion of men (59% versus 41%). There was only a slight predominance of nonsmokers (54.5%) compared to current or former smokers (45.5%). CONCLUSIONS: Patients with RET rearranged adenocarcinomas represent a rare and heterogeneous NSCLC subgroup. In some contrast to published data, we see a high prevalence of current and former smokers in our white RET cohort. The significance of co-occurring aberrations, so far, is unclear.
INTRODUCTION: Rearrangements of RET are rare oncogenic events in patients with non-small cell lung cancer (NSCLC). While the characterization of Asian patients suggests a predominance of nonsmokers of young age in this genetically defined lung cancer subgroup, little is known about the characteristics of non-Asian patients. We present the results of an analysis of a European cohort of patients with RET rearranged NSCLC. METHODS: Nine hundred ninety-seven patients with KRAS/EGFR/ALK wildtype lung adenocarcinomas were analyzed using fluorescence in situ hybridization for RET fusions. Tumor specimens were molecularly profiled and clinicopathological characteristics of the patients were collected. RESULTS: Rearrangements of RET were identified in 22 patients, with a prevalence of 2.2% in the KRAS/EGFR/ALK wildtype subgroup. Co-occurring genetic aberrations were detected in 10 patients, and the majority had mutations in TP53. The median age at diagnosis was 62 years (range, 39-80 years; mean ± SD, 61 ± 11.7 years) with a higher proportion of men (59% versus 41%). There was only a slight predominance of nonsmokers (54.5%) compared to current or former smokers (45.5%). CONCLUSIONS:Patients with RET rearranged adenocarcinomas represent a rare and heterogeneous NSCLC subgroup. In some contrast to published data, we see a high prevalence of current and former smokers in our white RET cohort. The significance of co-occurring aberrations, so far, is unclear.
Authors: Oliver Gautschi; Julie Milia; Thomas Filleron; Juergen Wolf; David P Carbone; Dwight Owen; Ross Camidge; Vignhesh Narayanan; Robert C Doebele; Benjamin Besse; Jordi Remon-Masip; Pasi A Janne; Mark M Awad; Nir Peled; Chul-Cho Byoung; Daniel D Karp; Michael Van Den Heuvel; Heather A Wakelee; Joel W Neal; Tony S K Mok; James C H Yang; Sai-Hong Ignatius Ou; Georg Pall; Patrizia Froesch; Gérard Zalcman; David R Gandara; Jonathan W Riess; Vamsidhar Velcheti; Kristin Zeidler; Joachim Diebold; Martin Früh; Sebastian Michels; Isabelle Monnet; Sanjay Popat; Rafael Rosell; Niki Karachaliou; Sacha I Rothschild; Jin-Yuan Shih; Arne Warth; Thomas Muley; Florian Cabillic; Julien Mazières; Alexander Drilon Journal: J Clin Oncol Date: 2017-03-13 Impact factor: 44.544
Authors: D Isla; M Majem; N Viñolas; A Artal; A Blasco; E Felip; P Garrido; J Remón; M Baquedano; J M Borrás; M Die Trill; R García-Campelo; O Juan; C León; P Lianes; F López-Ríos; L Molins; M Á Planchuelo; M Cobo; L Paz-Ares; J M Trigo; J de Castro Journal: Clin Transl Oncol Date: 2016-11-24 Impact factor: 3.405
Authors: Pierre Vanden Borre; Alexa B Schrock; Peter M Anderson; John C Morris; Andreas M Heilmann; Oliver Holmes; Kai Wang; Adrienne Johnson; Steven G Waguespack; Sai-Hong Ignatius Ou; Saad Khan; Kar-Ming Fung; Philip J Stephens; Rachel L Erlich; Vincent A Miller; Jeffrey S Ross; Siraj M Ali Journal: Oncologist Date: 2017-02-16
Authors: Anna Michelotti; Marco de Scordilli; Elisa Bertoli; Elisa De Carlo; Alessandro Del Conte; Alessandra Bearz Journal: Int J Mol Sci Date: 2022-06-17 Impact factor: 6.208